Eniola should open every section with IMPRINT as the hook — a Lagos-built addiction-liability screening SaaS that monetises a novel pharmacological insight (the CCT framework) no academic lab has published before, validated by Bayesian MCMC + ODE modelling and provisionally patented, with endorsements from Berridge, Gershman, Daw, and Mattar as the credibility layer. The Africa track removes her from global competition entirely. The 'zero to one' sentence to lead with: 'I built a tripartite pharmacological model that predicts addiction vulnerability before first use, validated it computationally, and am turning it into a SaaS screening tool from Lagos — without a PhD, without a lab, and without institutional funding.' Every form section should reinforce: the idea is original, the execution is real, the path to revenue exists, and this is precisely the bet no one else will take.